[go: up one dir, main page]

MX2009013765A - Polipeptidos y polinucleotidos para artemina y ligandos relacionados, y metodos de uso de los mismos. - Google Patents

Polipeptidos y polinucleotidos para artemina y ligandos relacionados, y metodos de uso de los mismos.

Info

Publication number
MX2009013765A
MX2009013765A MX2009013765A MX2009013765A MX2009013765A MX 2009013765 A MX2009013765 A MX 2009013765A MX 2009013765 A MX2009013765 A MX 2009013765A MX 2009013765 A MX2009013765 A MX 2009013765A MX 2009013765 A MX2009013765 A MX 2009013765A
Authority
MX
Mexico
Prior art keywords
cancer
polynucleotides
polypeptides
artemin
related ligands
Prior art date
Application number
MX2009013765A
Other languages
English (en)
Inventor
Dongxu Liu
Peter Edward Lobie
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of MX2009013765A publication Critical patent/MX2009013765A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)

Abstract

La invención abarca los polipéptidos, polinucleótidos y anticuerpos para la Artemina y ligandos relacionados incluyendo la Persefina (PSPN). La invención también abarca los vectores de expresión y las células hospederas para producir estos polipéptidos, polinucleótidos o anticuerpos. La invención abarca además el diagnóstico y la terapéutica, especialmente para el cáncer, y particularmente cáncer de mama, cáncer de colon, cáncer de próstata, cáncer endometrial, cáncer de pulmón, cáncer de estómago, cáncer de hígado y otros, que comprende uno o más de los polipéptidos, polinucleótidos, anticuerpos, vectores de expresión, células hospederas descritos, o composiciones de los mismos. Son abarcados particularmente los inhibidores de la Artemina y/o ligandos relacionados, y los usos para estos inhibidores.
MX2009013765A 2007-06-27 2008-06-25 Polipeptidos y polinucleotidos para artemina y ligandos relacionados, y metodos de uso de los mismos. MX2009013765A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94639407P 2007-06-27 2007-06-27
PCT/NZ2008/000152 WO2009002193A1 (en) 2007-06-27 2008-06-25 Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2009013765A true MX2009013765A (es) 2010-02-01

Family

ID=40185846

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013765A MX2009013765A (es) 2007-06-27 2008-06-25 Polipeptidos y polinucleotidos para artemina y ligandos relacionados, y metodos de uso de los mismos.

Country Status (8)

Country Link
US (2) US20110206673A1 (es)
EP (1) EP2164870B1 (es)
JP (1) JP2010534195A (es)
CN (1) CN101932602B (es)
AU (1) AU2008269689A1 (es)
CA (1) CA2691166A1 (es)
MX (1) MX2009013765A (es)
WO (1) WO2009002193A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012007316B1 (pt) 2009-09-30 2021-09-28 Evan V. Chrapko Método e sistemas para determinar a conectividade de rede
CN102711772A (zh) * 2009-10-16 2012-10-03 奥克兰联合服务有限公司 Artemin拮抗剂的抗肿瘤用途
US20110099164A1 (en) 2009-10-23 2011-04-28 Haim Zvi Melman Apparatus and method for search and retrieval of documents and advertising targeting
US20170358027A1 (en) 2010-01-14 2017-12-14 Www.Trustscience.Com Inc. Scoring trustworthiness, competence, and/or compatibility of any entity for activities including recruiting or hiring decisions, composing a team, insurance underwriting, credit decisions, or shortening or improving sales cycles
US9264329B2 (en) 2010-03-05 2016-02-16 Evan V Chrapko Calculating trust scores based on social graph statistics
WO2011134086A1 (en) 2010-04-30 2011-11-03 Evan V Chrapko Systems and methods for conducting reliable assessments with connectivity information
WO2013097026A1 (en) 2011-12-28 2013-07-04 Chrapko Evan V Systems and methods for visualizing social graphs
US9578043B2 (en) 2015-03-20 2017-02-21 Ashif Mawji Calculating a trust score
US20170235792A1 (en) 2016-02-17 2017-08-17 Www.Trustscience.Com Inc. Searching for entities based on trust score and geography
US9438619B1 (en) 2016-02-29 2016-09-06 Leo M. Chan Crowdsourcing of trustworthiness indicators
US9679254B1 (en) 2016-02-29 2017-06-13 Www.Trustscience.Com Inc. Extrapolating trends in trust scores
US9721296B1 (en) 2016-03-24 2017-08-01 Www.Trustscience.Com Inc. Learning an entity's trust model and risk tolerance to calculate a risk score
FR3058061A1 (fr) * 2016-10-27 2018-05-04 Selexel Nouvelle utilisation d'oligonucleotides double brin
US10180969B2 (en) 2017-03-22 2019-01-15 Www.Trustscience.Com Inc. Entity resolution and identity management in big, noisy, and/or unstructured data
WO2020132583A1 (en) * 2018-12-21 2020-06-25 Gloriana Therapeutics Sarl Mammalian cell culture-produced neublastin antibodies
GB2594317B (en) 2020-04-23 2022-05-25 Univ Johannesburg Witwatersrand SARS-CoV-2 Diagnostic control compositions
CN117177993B (zh) * 2021-04-20 2025-06-20 瑞泽恩制药公司 针对artemin的人抗体及其使用方法
CN113718029A (zh) * 2021-10-22 2021-11-30 中国人民解放军北部战区总医院 S100a4蛋白在动脉粥样硬化性肾动脉狭窄诊断中的应用
CN116515982A (zh) * 2022-04-24 2023-08-01 浙江大学 Ets2分子标志物在制备判断肝衰竭危险分层试剂的用途及试剂盒及应用
CN117700545B (zh) * 2023-10-26 2024-08-20 苏州系统医学研究所 靶向Artemin的抗体及其制备方法和在肿瘤治疗中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3483949D1 (de) 1983-09-26 1991-02-21 Udo Dr Med Ehrenfeld Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
CA2092323A1 (en) 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
DE69231736T2 (de) 1991-05-14 2001-10-25 The Immune Response Corp., Carlsbad Gerichtete abgabe von genen, die immunogene proteine kodieren
DE69231385T2 (de) 1991-06-05 2001-04-12 The Board Of Regents Acting For And On Behalf Of The Unversity Of Michigan, Ann Arbor Zielgerichtete freisetzung von genen, die sekretorische proteine kodieren
WO1993014188A1 (en) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
WO1993020221A1 (en) 1992-04-03 1993-10-14 Young Alexander T Gene therapy using targeted viral vectors
CA2592997A1 (en) 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
AU8126694A (en) 1993-10-26 1995-05-22 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
HK1045528B (zh) * 1998-07-14 2006-10-27 詹森药业有限公司 神经营养生长因子
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
DK1607402T3 (da) * 1999-03-08 2007-04-16 Genentech Inc Sammensætninger og fremgangsmåder til tumorbehandling
KR20050004240A (ko) * 1999-08-31 2005-01-12 제넨테크, 인크. 종양 치료용 조성물 및 방법
JP2004508019A (ja) * 2000-07-28 2004-03-18 コンピュジェン　インコーポレイテッド トランスクリプトームの中に場所を占めるｒｎａ転写物及びスプライス変異体を検出するためのオリゴヌクレオチドライブラリー
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
JP2008504803A (ja) * 2004-01-09 2008-02-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 遺伝子発現の細胞型特異的パターン
US20050186646A1 (en) * 2004-01-26 2005-08-25 Cruz Miguel A. Rapid assay to detect ADAMTS-13 activity

Also Published As

Publication number Publication date
AU2008269689A1 (en) 2008-12-31
EP2164870A4 (en) 2011-11-23
WO2009002193A1 (en) 2008-12-31
EP2164870A1 (en) 2010-03-24
US20110206673A1 (en) 2011-08-25
EP2164870B1 (en) 2015-12-09
US20150030605A1 (en) 2015-01-29
CN101932602A (zh) 2010-12-29
JP2010534195A (ja) 2010-11-04
CA2691166A1 (en) 2008-12-31
CN101932602B (zh) 2017-05-24

Similar Documents

Publication Publication Date Title
MX2009013765A (es) Polipeptidos y polinucleotidos para artemina y ligandos relacionados, y metodos de uso de los mismos.
CY1120300T1 (el) Αντισωματα ειδικα στην κλαουδινη 6 (cldn6)
MX340736B (es) Vacunas y componentes de vacunas para inhibicion de celulas microbianas.
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
PH12013502308A1 (en) Variant activin receptor polypeptides and uses thereof
EA201791940A2 (ru) Варианты полипептидов рецептора iib активина и их использование
DK1893196T3 (da) Diarylhydantoin-forbindelse
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
EP3858347A3 (en) Psma binding ligand-linker conjugates and methods for using
TW200740844A (en) Novel MAdCAM antibodies
WO2008121767A3 (en) Stitched polypeptides
WO2005123993A8 (en) Phage microarray profiling of the humoral response to disease
WO2016123591A3 (en) Compositions and methods for treatment and detection of cancers
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
MX2009009816A (es) Anticuerpos monoclonales para el tratamiento del cancer.
WO2006015079A3 (en) Erm family binding agents and their use in diagnosis and treatment of proliferative conditions
WO2009030770A3 (en) Methods and tools for prognosis of cancer in er- patients
MX2009001014A (es) Mediacion de citotoxicidad de celulas que evidencian expresion de cd63 en superficie.
WO2006095086A3 (fr) Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence.
WO2009049966A3 (en) Methods and tools for prognosis of cancer in her2+ patients
WO2007059190A3 (en) Compositions of and methods of using stabilized psma dimers
WO2008034909A3 (en) Second line treatment of metastatic hormone refractory prostate cancer using satraplatin
ATE435224T1 (de) Neue piperidinsubstituierte diaminothiazole

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal